Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countriesnews2024-10-02T23:12:20+00:00October 2nd, 2024|The New York Times|
Six Reasons Drug Prices Are So High in the U.S.news2024-01-17T18:53:05+00:00January 17th, 2024|The New York Times|
Monica Bertagnolli, NIH’s New Leader, Wants to Broaden Participation in Medical Researchnews2023-12-25T10:00:53+00:00December 25th, 2023|The New York Times|
Common Patenting Tactic by Drug Companies May Be Illegal, F.T.C. Saysnews2023-09-14T18:20:16+00:00September 14th, 2023|The New York Times|
Why One Drug Company Held Back a Better Drugnews2023-09-07T10:00:12+00:00September 7th, 2023|The New York Times|
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapynews2023-07-22T18:26:55+00:00July 22nd, 2023|The New York Times|
Gilead Wins Key Patent Rights Suit Over HIV Prevention Drug PrEPnews2023-05-09T17:34:57+00:00May 9th, 2023|The New York Times|
A Drug Company Exploited a Safety Requirement to Make Moneynews2023-02-28T08:00:08+00:00February 28th, 2023|The New York Times|
‘Miracle’ Cystic Fibrosis Drug Kept Out of Reach in Developing Countriesnews2023-02-07T21:15:45+00:00February 7th, 2023|The New York Times|
How a Drug Company Made $114 Billion by Gaming the U.S. Patent Systemnews2023-01-28T17:39:16+00:00January 28th, 2023|The New York Times|
